07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Gilead, Cadila Pharmaceuticals, Cipla, Hetero Drugs, Mylan, Ranbaxy, SeQuent Scientific, Strides Arcolab deal

Gilead signed non-exclusive licensing agreements allowing seven generic manufacturers to produce and market its chronic HCV drugs sofosbuvir and sofosbuvir/ledipasvir in 91 developing countries. Gilead said the deals are part of the company's humanitarian program...
01:50 , Sep 16, 2014 |  BC Extra  |  Company News

Gilead licenses HCV drugs to Indian generic makers

Gilead Sciences Inc. (NASDAQ:GILD) signed non-exclusive licensing agreements allowing seven Indian generics companies to manufacture its chronic HCV drugs sofosbuvir and sofosbuvir/ledipasvir for distribution in 91 developing countries. Licensees will be able to set their...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Cadila Pharmaceuticals, NovaSaid deal

NovaSaid and Cadila partnered to develop NovaSaid's therapeutic candidates for inflammation and pain, including rheumatoid arthritis (RA). The companies will collaborate on preclinical and clinical testing. Development will be conducted at Cadila's facility in Ahmedabad,...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Cadila Pharmaceuticals, Helperby Therapeutics deal

Antibiotic company Helperby granted Cadila worldwide development and commercialization rights to HT61 , an undisclosed topical compound that improves the efficacy of existing antibiotics against highly resistant bacteria. HT61 has completed a Phase II trial...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Pandemic H1N1 influenza vaccine: Phase I started

Novavax disclosed in its 2012 earnings that CPL Biologicals Pvt. Ltd. began an Indian Phase I trial to evaluate its pandemic H1N1 influenza vaccine. Novavax said the vaccine was manufactured in India using its gene...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Trivalent seasonal influenza vaccine: Phase I started

Novavax disclosed in its 2012 earnings that CPL Biologicals Pvt. Ltd. began an Indian Phase I trial to evaluate its trivalent seasonal influenza vaccine. Novavax said the vaccine was manufactured in India using Novavax's gene...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

Cadila Pharmaceuticals, Pergamum deal

The companies partnered to develop and commercialize an undisclosed therapeutic peptide to treat infectious diseases. Development of the compound will be conducted at Cadila, which will be responsible for all costs up to Phase II...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Cadila Pharmaceuticals, Novavax, International Centre for Genetic Engineering and Biotechnology deal

Novavax and the center partnered to develop a malaria vaccine using Novavax's virus-like particle (VLP) technology in India with funding from India's Department of Biotechnology Vaccine Grand Challenge Program. CPL Biologicals Pvt. Ltd., a JV...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

What might fit

What might fit Company Product Description Indication Status Arca biopharma Inc. (NASDAQ:ABIO) Gencaro bucindolol Non-selective beta blocker Chronic heart failure FDA complete response letter in June requests additional clinical trials AtheroGenics Inc. (A) AGI-1067 Small...
07:00 , Jul 13, 2009 |  BC Week In Review  |  Company News

Novavax, Cadila Pharmaceuticals deal

Novavax and Cadila launched CPL Biologicals Pvt. Ltd, a JV to develop and commercialize vaccines, pharmaceuticals and diagnostics in India. The JV was formed in March (see BioCentury, April 6). Novavax Inc. (NASDAQ:NVAX), Rockville, Md....